Journal of Hepatology
Volume 53, Issue 1 , Pages 179-190 , July 2010

Cirrhotic cardiomyopathy

  • Søren Møller

      Affiliations

    • Corresponding Author InformationCorresponding author at: Department of Clinical Physiology and Nuclear Medicine, 239, Hvidovre Hospital, DK-2650 Hvidovre, Faculty of Health Sciences, University of Copenhagen, Denmark. Tel.: +45 3632 3568; fax: +45 3632 3750.
    • ,
  • Jens H. Henriksen

References 

  1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennecs cirrhosis. J Clin Invest. 1953;32:1025–1033
  2. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;5:1151–1157
  3. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In:  Gines P,  Arroyo V,  Rodes J,  Schrier RW editor. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 2005;p. 139–155
  4. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121–S131
  5. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol. 2007;292:H2966–H2972
  6. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart. 2002;87:9–15
  7. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis. 2008;28:59–69
  8. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006;44:994–1002
  9. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57:268–278
  10. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q–T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27:28–34
  11. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104:2458–2466
  12. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42:68–74
  13. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol. 1999;276:G1043–G1051
  14. Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol. 1998;29:328–341
  15. Bernardi M, Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In:  Ginés P,  Arroyo V,  Rodes J,  Schrier RW editor. Ascites and renal dysfunction in liver disease. Malden: Blackwell Publishing Ltd.; 2005;p. 43–54
  16. Møller S, Bendtsen F, Henriksen JH. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scand J Gastroenterol. 2006;41:451–458
  17. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology. 1994;20:1343–1350
  18. Castro A, Jimenez W, Claria J, Ros J, Martinez JM, Bosch M, et al. Impaired responsiveness to angiotensin-II in experimental cirrhosis – role of nitric oxide. Hepatology. 1993;18:367–372
  19. Polio J, Sieber CC, Lerner E, Groszmann RJ. Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal-hypertensive and aged rats. Hepatology. 1993;18:128–136
  20. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut. 2008;57:1300–1314
  21. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol. 2003;38:44–50
  22. Dillon JF, Nolan J, Thomas H, Williams BC, Neilson JMM, Bouchier IAD, et al. The correction of autonomic dysfunction in cirrhosis by captopril. J Hepatol. 1997;26:331–335
  23. Trevisani F, Sica G, Mainqua P, Santese G, De Notariis S, Caraceni P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology. 1999;30:1387–1392
  24. Dumcke CW, Møller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand J Clin Lab Invest. 2008;1–11
  25. Laffi G, Lagi A, Cipriani M, Barletta G, Bernardi L, Fattorini L, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology. 1996;24:1063–1067
  26. Mani AR, Montagnese S, Jackson CD, Jenkins CW, Head IM, Stephens RC, et al. Decreased heart rate variability in patients with cirrhosis relates to the presence and severity of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2008;296:G330–G338
  27. Gerbes AL, Remien J, Jüngst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet. 1986;1:1409–1411
  28. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology. 1990;12:481–485
  29. Mani AR, Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. Hepatology. 2006;43:847–856
  30. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994;267:G87–G93
  31. Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110:1191–1198
  32. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol. 1997;26:904–912
  33. Ceolotto G, Papparella I, Sticca A, Bova S, Cavalli M, Cargnelli G, et al. An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology. 2008;48:1913–1923
  34. Jaue DN, Ma ZH, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology. 1997;25:1361–1365
  35. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol. 2006;12:837–842
  36. Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. v. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2008;295:G649–G653
  37. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol. 2005;146:315–323
  38. Batkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol. 2007;293:H1689–H1695
  39. Van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol. 1996;24:747–752
  40. Garcia-Estan J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond). 2002;102:213–222
  41. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000;118:937–944
  42. Inserte J, Perello A, Agullo L, Ruiz-Meana M, Schluter KD, Escalona N, et al. Left ventricular hypertrophy in rats with biliary cirrhosis. Hepatology. 2003;38:589–598
  43. Honar H, Glenn TK, Zhang M, Keurs H, Lee SS. Characterization of cardiac contractility and mechanical behavior of the heart in a rat model of cirrhotic cardiomyopathy: the role of beta-myosin heavy chain overexpression. Hepatology. 2008;48:1060Α
  44. Glenn TK, Honar H, Liu H, Keurs H, Lee SS. Role of titin and collagen in the diastolic dysfunction of cirrhotic cardiomyopathy. Hepatology. 2008;48:1060Α
  45. Liu H, Song D, Lee SS. Role of heme oxygenase–carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol. 2001;280:G68–G74
  46. Liu H, Lee SS. Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int. 2008;28:640–648
  47. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol. 2006;3:329–337
  48. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol. 1997;273:G537–G544
  49. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology. 2001;121:1209–1218
  50. Zavecz JH, Bueno O, Maloney RE, ODonnell JM, Roerig SC, Battarbee HD. Cardiac excitation–contraction coupling in the portal hypertensive rat. Am J Physiol Gastrointest Liver Physiol. 2000;279:G28–G39
  51. Tavakoli S, Hajrasouliha AR, Jabehdar-Maralani P, Ebrahimi F, Solhpour A, Sadeghipour H, et al. Reduced susceptibility to epinephrine-induced arrhythmias in cirrhotic rats: the roles of nitric oxide and endogenous opioid peptides. J Hepatol. 2007;46:432–439
  52. Keller H, Bezjak V, Stegaru B, Buss J, Holm E, Heene DL. Ventricular function in cirrhosis and portosystemic shunt: a two-dimensional echocardiographic study. Hepatology. 1988;8:658–662
  53. Ahmed SS, Howard M, Hove Wt, Leevy CM, Regan TJ. Cardiac function in alcoholics with cirrhosis: absence of overt cardiomyopathy – myth or fact?. JACC. 1984;3:696–702
  54. Gould L, Shariff M, Zahir M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest. 1969;48:860–864
  55. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol. 2001;36:785–794
  56. Kelbæk H, Rabøl A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, et al. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin Physiol. 1987;7:35–41
  57. Bernardi M, Rubboli A, trevisani F, Cancellieri C, Ligabue A, Baradini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol. 1991;12:207–216
  58. Limas CJ, Guiha NH, Lekagul O. Impaired left ventricular function in alcoholic cirrhosis with ascites. J Lab Clin Med. 1977;89:1175–1187
  59. Mikulic E, Munoz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther. 1983;34:56–59
  60. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation. 1996;61:1180–1188
  61. Krag A, Bendtsen F, Henriksen JH, Møller S. Cardiac effects of terlipressin in cirrhosis. Unmasking a cirrhotic cardiomyopathy. J Hepatol. 2007;46:S96
  62. Kim Y, Baik SK, Suk KT, Kim JW, Kim HS, Kwon SO, et al. Dobutamine stress echocardiography: a new screening method for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Hepatology. 2008;48:1064Α
  63. Krag A, Bendtsen F, Kjaer A, Leth-Petersen C, Møller S. Cardiac function studied by dobutamin stress MRI in patients with mild cirrhosis. J Hepatol. 2009;50:S277
  64. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology. 1995;22:472–478
  65. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol. 1996;31:279–284
  66. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol. 2000;95:3200–3205
  67. Gerbes AL, Wernze H, Arendt RM, Riedel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology. 1989;9:417–422
  68. Rector WG, Adair O, Hossack KF, Rainquet S. Atrial volume in cirrhosis: relationship to blood volume and plasma concentrations of atrial natriuretic factor. Gastroenterology. 1990;99:766–770
  69. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci. 1999;97:259–267
  70. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology. 1999;29:640–643
  71. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–366
  72. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. Clin Sci (Lond). 2001;101:621–628
  73. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52:1511–1517
  74. Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol. 2005;20:1115–1120
  75. Bernal V, Pascual I, Esquivias P, Garcia-Gil A, Fernandez C, Mateo JM, et al. Cardiac hemodynamic profiles and pro-B-type natriuretic peptide in cirrhotic patients undergoing liver transplantation. Transpl Proc. 2009;41:985–986
  76. Goetze JP, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest. 2006;36:8–15
  77. Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci. 1998;43:1701–1707
  78. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IAD, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;22:326–332
  79. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49:268–275
  80. Ruiz-Del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–447
  81. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–110
  82. Fields NG, Yuan BX, Leenen FH. Sodium-induced cardiac hypertrophy. Cardiac sympathetic activity versus volume load. Circ Res. 1991;68:745–755
  83. Ruiz-Del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210–1218
  84. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996;24:451–459
  85. Schmieder RE. Salt intake is related to the process of myocardial hypertrophy in essential hypertension. JAMA. 1989;262:1187–1188
  86. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26:1131–1137
  87. LaVilla G, Laffi G. Atrial natriuretic peptide and other natriuretic factors in cirrhosis. In:  Gines P,  Arroyo V,  Rodes J,  Schrier RW editor. Ascites and renal dysfunction. Malden: Blackwell Publishing; 2005;p. 73–83
  88. Nazar A, Sitges M, Guevara M, Terra C, Marinelli A, Villa F, et al. Cardiomyopathy in patients with cirrhosis. Frequency, characteristics and relationship with circulatory dysfunction and prognosis. Journal of Hepatology. 2009;50:S85
  89. De BK, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S, et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. J Hepatol. 2003;39:315–319
  90. Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med. 2007;55:341–359
  91. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rôssle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut. 1999;44:743–748
  92. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002;97:142–148
  93. Kovacs A, Schepke M, Heller J, Schild HH, Flacke S. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: Preliminary results. Cardiovasc Intervent Radiol. 2010;33:290–296
  94. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut. 2007;56:869–875
  95. Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario. J Gastroenterol Hepatol. 2007;22:395–399
  96. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl. 2002;8:690–700
  97. Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol. 2005;51:179–186
  98. Day PC, James FWO, Butler JT, Campbell RWF. Q–T prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet. 1993;341:1423–1428
  99. Kempler P, Varadi A, Kadar E, Szalay F. Autonomic and peripheral neuropathy in primary biliary cirrhosis: evidence of small sensory fibre damage and prolongation of the QT interval. J Hepatol. 1994;21:1150–1151
  100. Lazzeri C, Lavilla G, Laffi G, Vecchiarino S, Gambilonghi F, Gentilini P, et al. Autonomic regulation of heart rate and QT interval in nonalcoholic cirrhosis with ascites. Digestion. 1997;58:580–586
  101. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology. 1996;23:1128–1134
  102. Garcia GM, Hernandez-Madrid A, Lopez-Sanroman A, Candela A, Nuno J, Barcena R. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. Transpl Proc. 1999;31:2366–2367
  103. Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J Hepatol. 2001;35:733–738
  104. Carey EJ, Douglas DD. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease. Dig Dis Sci. 2005;50:320–323
  105. Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol. 2005;95:691–694
  106. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int. 2003;23:243–248
  107. Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol. 2003;38:461–467
  108. Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, Pieruzzi F, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond). 2008;116:851–859
  109. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q–T(c) interval in mild portal hypertensive cirrhosis. J Hepatol. 2005;43:637–644
  110. Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q–T interval (QTc) in patients with cirrhosis. J Hepatol. 2004;40:239–246
  111. Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol. 2008;48:415–421
  112. Hansen S, Møller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol. 2007;47:373–380
  113. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002;36:513–520
  114. Veglio F, Melchio R, Calva S, Rabbia F, Gallo V, Melino P, et al. Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver. 1998;18:420–426
  115. Møller S, Iversen JS, Krag A, Bendtsen F. Relation between baroreflex sensitivity and pulmonary dysfunction in cirrhosis: effect of hyperoxia. J Hepatol. 2009;50:S84
  116. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient – preliminary report of a prospective study. Hepatology. 1994;19:129–132
  117. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology. 1995;21:986–994
  118. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995;122:816–822
  119. Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut. 1996;39:600–604
  120. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29:632–639
  121. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64
  122. Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest. 1995;107:1467–1469
  123. Rodriguez-Laiz JM, Banares R, Echenagusia A, Casado M, Camunez F, Perezroldan F, et al. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension: preliminary results. Dig Dis Sci. 1995;40:2121–2127
  124. Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, et al. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J Clin Gastroenterol. 2004;38:590–594
  125. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123:1839–1847
  126. Vanderlinden P, Lemoine O, Ghysels M, Ortinez M, Deviere J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology. 1996;23:982–987
  127. Henderson JM, Mackay GJ, Hooks M, Chezmar JL, Galloway JR, Dodson TF, et al. High cardiac output of advanced liver diseases persists after orthotopic liver transplantation. Hepatology. 1992;15:258–262
  128. Navasa M, Feu F, Garciapagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology. 1993;17:355–360
  129. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology. 1999;30:58–64
  130. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000;6:S44–S52
  131. Ripoll C, Catalina MV, Yotti R, Olmedilla L, Perez-Pena J, Lo IO, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation. 2008;85:1766–1772
  132. Gadano A, Hadengue A, Widmann JJ, Vachiery F, Moreau R, Yang S, et al. Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology. 1995;22:458–465
  133. Carey EJ, Gautam M, Ingall T, Douglas DD. The effect of liver transplantation on autonomic dysfunction in patients with end-stage liver disease. Liver Transpl. 2008;14:235–239

PII: S0168-8278(10)00194-7

doi: 10.1016/j.jhep.2010.02.023

Journal of Hepatology
Volume 53, Issue 1 , Pages 179-190 , July 2010

Article Tools

* Image Usage & Resolution